The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

Peer Review reports

Original Submission
8 Jul 2016	Submitted	Original manuscript
4 Aug 2016	Author responded	Author comments - Michele Guida
Resubmission - Version 2
4 Aug 2016	Submitted	Manuscript version 2
13 Feb 2017	Reviewed	Reviewer Report - David Melton
22 Feb 2017	Reviewed	Reviewer Report - Nikola Bowden
15 Apr 2017	Author responded	Author comments - Michele Guida
Resubmission - Version 3
15 Apr 2017	Submitted	Manuscript version 3
20 Apr 2017	Reviewed	Reviewer Report - David Melton
20 Feb 2018	Author responded	Author comments - Michele Guida
Resubmission - Version 4
20 Feb 2018	Submitted	Manuscript version 4
21 Mar 2018	Author responded	Author comments - Michele Guida
Resubmission - Version 5
21 Mar 2018	Submitted	Manuscript version 5
30 Apr 2018	Author responded	Author comments - Michele Guida
Resubmission - Version 6
30 Apr 2018	Submitted	Manuscript version 6
Publishing
2 May 2018	Editorially accepted
10 May 2018	Article published	10.1186/s12885-018-4479-2

Back to article page